Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development
Back

Psychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream Media

May 21, 2021 • 6:27 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

2021 has been a banner year for the psychedelic therapy market and we believe the industry is in the early innings of a major growth cycle. 

With interest growing for data from biotech and non-profit research firms that are conducting Food and Drug Administration (FDA) clinical trials on psychedelic therapies. The clinical studies are focused primarily on mental health illnesses and we are favorable on how these breakthrough therapies can help patients that are impacted by debilitating mental health disorders. 

The current state of the psychedelic therapy market looks similar to the cannabis industry in 2016. We expect the psychedelic industry to benefit from positive clinical data that is being published by biotech and non-profit research firms. 

In 2016, GW Pharmaceuticals plc (GWPH) reported positive Phase 3 clinical data and the development served as a catalyst for the entire cannabis sector. The cannabis biotech firm was recently acquired by Jazz Pharmaceuticals plc (JAZZ) and we expect to see similar transactions in the psychedelic industry once these firms start to report positive clinical data.

The COVID pandemic has only stressed the need for better treatments from mental illnesses. Two of the indications that are being studied by psychedelic therapy firms are major depressive disorder (MDD) and post-traumatic-stress-disorder (PTSD). We believe these indications have massive total addressable markets (TAMs) and are favorable on the potential value that can be created for firms that successfully develop a treatment for them.

Earlier this month, Nature published the results from a Phase 3 clinical trial on MDMA as a treatment for PTSD. The study was conducted by the Multidisciplinary Association of Psychedelic Studies (MAPS) and the data that was reported was positive. According to the study, 67% of participants receiving MDMA therapy reported a reduction in symptoms after 18 weeks and three sessions.

Patients who received the therapy reported a substantial decrease in the number nightmares they have. Less than a third of the control group had similar outcomes and the data shows that adding MDMA to the treatment regimen helps patients overcome PTSD faster.

Over the next year, we expect to receive clinical data from companies like MAPS, Cybin, and ATAI Life Sciences. We believe the industry has substantial growth prospects and will monitor how it benefits from positive clinical trial data. 

If you are interested in learning about psychedelic therapy companies that are in advanced clinical trials, please send an email to support@technical420.com with the subject “Biotech Psychedelic Companies” to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link